Anti-NFIA Polyclonal Antibody from ProteoGenix; catalogue ARO-A22130; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Anti-NFIA Polyclonal Antibody: A Powerful Tool for Studying Neurodevelopmental Disorders
The Anti-NFIA Polyclonal Antibody is a highly specific and sensitive tool for researchers studying neurodevelopmental disorders. This antibody is designed to target and detect the nuclear factor IA (NFIA) protein, a key regulator of neural development. Its unique properties make it an essential tool for understanding the molecular mechanisms underlying brain development and disorders.
NFIA is a transcription factor that plays a crucial role in the development and maturation of the central nervous system. It regulates the expression of genes involved in cell proliferation, differentiation, and migration, making it a critical player in neurodevelopmental processes. Dysregulation of NFIA has been linked to a variety of neurodevelopmental disorders, including autism spectrum disorder, schizophrenia, and intellectual disability.
The Anti-NFIA Polyclonal Antibody is an invaluable tool for researchers studying neurodevelopmental disorders. Its high specificity and sensitivity make it suitable for a variety of applications, including:
1. Immunohistochemistry (IHC) and Immunofluorescence (IF): The antibody can be used in IHC and IF to detect the expression and localization of NFIA in tissue samples. This allows researchers to visualize the distribution of NFIA in the brain and study its role in different developmental stages.
2. Western Blotting (WB): WB can be used to analyze the protein levels of NFIA in cell or tissue lysates. This technique is useful for studying the expression of NFIA in different brain regions and identifying potential changes in NFIA levels in diseased states.
3. Chromatin Immunoprecipitation (ChIP): ChIP can be used to study the binding of NFIA to specific DNA regions, providing valuable insights into its role as a transcription factor in neurodevelopment.
The Anti-NFIA Polyclonal Antibody has been extensively validated in various experimental settings. Some notable examples include:
1. In a study published in the Journal of Neuroscience, researchers used the antibody to investigate the role of NFIA in regulating the development of oligodendrocytes, a type of brain cell essential for proper neuronal function.
2. In another study published in Molecular Psychiatry, the antibody was used to study the role of NFIA in the development of the prefrontal cortex, a brain region implicated in several neurodevelopmental disorders.
3. The antibody has also been used in studies exploring the role of NFIA in brain tumors, providing valuable insights into its potential as a therapeutic target.
Conclusion:
In conclusion, the Anti-NFIA Polyclonal Antibody is a powerful tool for studying neurodevelopmental disorders. Its high specificity and sensitivity make it suitable for a variety of applications, and its use in validated experimental studies further highlights its reliability and effectiveness. Add this antibody to your research arsenal and gain a deeper understanding of the molecular mechanisms underlying neurodevelopmental disorders.
ProteoGenix catalogue number ARO-A22130. For research use only.
Target: Nuclear factor 1 A-type; NF1-A; Nuclear factor 1/A; CCAAT-box-binding transcription factor; CTF; Nuclear factor I/A; NF-I/A; NFI-A; TGGCA-binding protein; Nfia; Clonality: Polyclonal Antibody; Applications: ELISA, IHC.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | IHC |
|---|---|---|---|---|---|---|---|---|---|
| Nuclear factor 1 A-type; NF1-A; Nuclear factor 1/A; CCAAT-box-binding transcription factor; CTF; Nuclear factor I/A; NF-I/A; NFI-A; TGGCA-binding protein; Nfia |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
